EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Computationally accelerated identification of P-glycoprotein inhibitors

Lauren A McCormick iD, James W McCormick, Chanyang Park, Courtney A Follit, John G Wise, Pia D Vogel

PLOS One · 2025

DOI: 10.1371/journal.pone.0325121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Lauren A McCormick und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Southern Methodist University, Dallas, Texas, United States of America. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Member 1, Drug Discovery, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health's (NIH) National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overexpression of the polyspecific efflux transporter, P-glycoprotein (P-gp, MDR1, ABCB1 ), is a major mechanism by which cancer cells acquire multidrug resistance (MDR), the resistance to diverse chemotherapeutic drugs. Inhibiting drug transport by P-gp can resensitize cancer cells to chemotherapy, but there are no P-gp inhibitors available to patients. Clinically unsuccessful P-gp inhibitors tend to bind at the pump’s transmembrane drug binding domains and are often P-gp transport substrates, resulting in lowered intracellular concentration of the drug and altered pharmacokinetics. In prior work, we used computationally accelerated drug discovery to identify novel P-gp inhibitors that target the pump’s cytoplasmic nucleotide binding domains. Our first-draft study provided conclusive evidence that the nucleotide binding domains of P-gp are viable targets for drug discovery. Here we develop an enhanced, computationally accelerated drug discovery pipeline that expands upon our prior work by iteratively screening compounds against multiple conformations of P-gp with molecular docking. Targeted molecular dynamics simulations with our homology model of human P-gp were used to generate docking receptors in conformations mimicking a putative drug transport cycle. We offset the increased computational complexity using custom Tanimoto chemical datasets, which maximize the chemical diversity of ligands screened by docking. Using our expanded, virtual-assisted pipeline, we identified nine novel P-gp inhibitors that reverse MDR in two types of P-gp overexpressing human cancer cell lines, reflecting a 13.4% hit rate. Of these inhibitors, all were non-toxic to non-cancerous human cells, and six were not likely to be transport substrates of P-gp. Our novel P-gp inhibitors are chemically diverse and are good candidates for lead optimization. Our results demonstrate that the nucleotide binding domains of P-gp are an underappreciated target in the effort to reverse P-gp-mediated multidrug resistance in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Binding Cassette Transporter, Subfamily B, Member 1Drug DiscoveryAntineoplastic AgentsHumansMolecular Docking SimulationMolecular Dynamics SimulationDrug Resistance, NeoplasmATP Binding Cassette Transporter, Subfamily BDrug Resistance, Multiple

Substanzen

ATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily BAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biological Sciences, Southern Methodist University, Dallas, Texas, United States of America.
  • Center for Drug Discovery, Design and Delivery, Southern Methodist University, Dallas, Texas, United States of America.
  • Center for Scientific Computation, Southern Methodist University, Dallas, Texas, United States of America.

ORCID-Profile: Lauren A McCormick

Förderung

  • NIGMS NIH HHS
  • National Institutes of Health's (NIH) National Institute of General Medical Sciences

Zitieren

APA

McCormick, L. A., McCormick, J. W., Park, C., Follit, C. A., Wise, J. G., & Vogel, P. D. (2025). Computationally accelerated identification of P-glycoprotein inhibitors. PLOS One. https://doi.org/10.1371/journal.pone.0325121

Vancouver

McCormick LA, McCormick JW, Park C, Follit CA, Wise JG, Vogel PD. Computationally accelerated identification of P-glycoprotein inhibitors. PLOS One. 2025. doi:10.1371/journal.pone.0325121

BibTeX
@article{McCormick2025,
  author = {McCormick, Lauren A and McCormick, James W and Park, Chanyang and Follit, Courtney A and Wise, John G and Vogel, Pia D},
  title = {Computationally accelerated identification of P-glycoprotein inhibitors},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0325121}
}
Kostenlos starten →